Curaleaf reported a larger-than-expected quarterly loss, even as revenue growth and signs of improving business momentum offered some support.
Curaleaf Holdings Inc. (TSX: CURA) reported adjusted earnings per share of -US$0.1729 for the quarter ended September 30, 2026. That was 15.3% below the -US$0.15 estimate. The result ends a run of two consecutive estimate beats, though Curaleaf had beaten estimates in three of its last four reported quarters. For Canadian investors, the loss comes as the company expands across cannabis markets and remains involved in a contested bid for Aurora Cannabis. Here’s what the latest figures tell us—and what they don’t.
Recent earnings trend
Curaleaf Holdings Inc.
CURA.TO
CURA.TO
Curaleaf Holdings Inc.
WealthAwesomeMarket cap
$3.50B
52W high
$20.93
52W low
$7.77
1W change
+12.51%
Beta
1.76
Analyst Price Targets
Based on analyst covering CURA · as of Nov 6, 2026
Wall Street analysts forecast CURA stock price to rise 37.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.19
+37.6% Upside
Previously C$18.08 on Nov 5, 2026
Current Price
C$13.22
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CURA's historical volatility
30-Day Vol
64.7%
Annualized
90-Day Vol
61.6%
Annualized
Trend (90d)
-18.0%
Annualized drift
90d Mean
C$12.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.94 | C$10.35 – C$16.18 |
| 60 trading days | C$12.66 | C$9.24 – C$17.37 |
| 90 trading days | C$12.40 | C$8.42 – C$18.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-02-25 | — | -0.2100 | — |
| 2026-09-30 | 2026-11-03 | -0.1729 | -0.1500 | -15.3% |
| 2026-06-30 | 2026-08-05 | 0.0700 | -0.2400 | +129.2% |
| 2026-03-31 | 2026-05-04 | 0.2900 | -0.2700 | +207.4% |
| 2025-12-31 | 2026-02-26 | -0.0500 | -0.0900 | +44.4% |
| 2025-09-30 | 2025-11-04 | -0.1900 | -0.2400 | +20.8% |
Investor takeaway: CURA’s EPS miss is a setback, but one quarter doesn’t erase its recent estimate beats or reported revenue growth. The earnings data provided doesn’t include actual quarterly revenue or margins, so the EPS surprise alone doesn’t show how the business performed. Watch profitability, pricing pressure and the cost of Curaleaf’s expansion plans.
EPS: -US$0.1729 vs. -US$0.15 estimate
Curaleaf missed the quarterly EPS estimate by 15.3%. It had beaten estimates in three of its previous four reported quarters, making this a break from its recent pattern. The available earnings data doesn’t include actual revenue or margins for the quarter.
Bull case
Curaleaf has shown signs of growth. Company figures cited for the first half of 2026 show revenue up 8% year over year, international revenue up 30%, and a second-quarter gross margin of 50%. The latest EPS miss is one quarter in a period when Curaleaf beat estimates three times in four quarters. If revenue growth and cost controls lead to stronger earnings, the company could regain momentum.
Bear case
Curaleaf’s quarterly loss was wider than expected, and its trailing-twelve-month EPS remains negative. Its profit margin is -0.76%. Earlier business updates also pointed to a lower adjusted EBITDA margin and continued retail pricing pressure. The proposed Aurora acquisition brings added execution and financing risks, and the bid remains contested. The results provided don’t show that Curaleaf is on a path back to profitability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
